Illustrative image – not actual.Ahmedabad-based Roselabs Biosciences is planning to raise Rs 100 crore for its expansion plan.
For this purpose, the company is in talks with three private equity players and expects to finalise the deal by October 2013. The funds will be utilised for a new project wherein the company will set up a backward integrated unit using its own in-house developed Active Pharmaceutical Ingredient (API), and some rare off-patent molecules. Roselabs is expecting to commence work on the project by January 2014. Recently, the company invested Rs 400 crore in setting up the pre-filled syringes (PFS) facility near Ahmedabad, Gujarat.
The company has signed a supply contract worth $20 million (approx Rs 131.32 crore) with a Brazilian drugmaker. It will supply branded formulation PFS products to the Brazilian company, which will market them. To start with, there will be four products, out of which two will be biotech products.
